First-line boosted protease inhibitor-based regimens in treatment-naive hiv-1-infected patients - Making a good thing better

AIDS Reviews

Volumn 11, Issue 4, 2009, Pages 215-222

  Llibre, Josep M ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Atazanavir; Darunavir; HIV 1; Initial therapy; Protease inhibitors

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTIVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; CD4 ANTIGEN; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL; VIRUS RNA;

ANTIVIRAL ACTIVITY; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG CHOICE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; GENETIC RESISTANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERBILIRUBINEMIA; JAUNDICE; NAUSEA; PRACTICE GUIDELINE; RASH; REVIEW; SENSITIVITY ANALYSIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT FAILURE; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; HIV-1; HTLV-I INFECTIONS; HUMANS; PROTEASE INHIBITORS; TREATMENT OUTCOME; VIREMIA;

EID: 74249094258     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced HIV infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-60.
2. Mocroft A, Vella S, Benfield T, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet. 1998;352:1725-30.
3. Centers for Disease Control and Prevention. Report of the NIH Panel to Define Principles of Therapy of HIV Infection and Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. MMWR. 1998;47:43-83.
4. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. November 3, 2008. Available at http://www.aidsinfo.nih.gov/ContentFiles/Adultand-AdolescentGL.pdf.
5. Walmsley S. Protease inhibitor-based regimens for HIV therapy: safety and efficacy. J Acquir Immune Defic Syndr. 2007;45(Suppl 1):5-13.
6. Miller M, Jaskolski M, Rao J, Leis J, Wlodawer A. Crystal structure of a retroviral protease proves relationship to aspartic protease family. Nature. 1989;337:576-9.
7. Lefebvre E, Schiffer C. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev. 2008;10:131-42.
8. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346: 2039-46.
9. Hammer S, Eron J, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300:555-70.
10. Kempf D, King M, Bernstein B, et al. Incidence of resistance in a doubleblind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis. 2004;189:51-60.
11. Nijhuis M, Wensing A, Bierman W, et al. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V. J Infect Dis. 2009;200:698-709.
12. Eron J, Yeni P, Gathe J, et al. The KLEAN study of fosamprenavir- ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lami-vudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet. 2006;368:476-82.
13. Walmsley S, Avihingsanon A, Slim J, et al. Gemini: a non-inferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr. 2009;50:367-74.
14. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372:646-55.
15. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2008;22:1389-97.
16. Bartlett J, Buda J, Von S, et al. Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview. J Acquir Immune Defic Syndr. 2006;41:323-31.
17. Lima V, Gill V, Yip B, Hogg R, Montaner J, Harrigan P. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy. J Infect Dis. 2008;198:51-8.
18. Riddler S, Haubrich R, Di Rienzo A, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095-106.
19. Sherman D, Fish D. Management of protease inhibitor-associated diarrhea. Clin Infect Dis. 2000;30:908-14.
20. Lundgren J, Reiss P, Worn S, et al. Risk of Myocardial Infarction with Exposure to Specific ARV from the PI, NNRTI, and NRTI Drug Classes: The D:A:D Study. Program and abstracts of the 16th CROI. Montreal, Canada. February, 2009 [abstract 44LB].
21. Lang S, Mary-Krause M, Cotte L, et al. Impact of Specific NRTI and PI Exposure on the Risk of Myocardial Infarction. A Case-Control Study Nested within the French Hospital Database on HIV ANRS CO4. Program and abstracts of the 16th CROI Montreal, Canada. February, 2009 [abstract 43LB].
22. Gathe J, da Silva B, Cohen D, et al. A once-daily lopinavir/ritonavir- based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. J Acquir Immune Defic Syndr. 2009;50:474-81.
23. Gross R, Tierney C, Andrade A, et al. Modified directly observed antiretroviral therapy compared with self-administered therapy in treatmentnaive HIV-1-infected patients: A randomized trial. Arch Intern Med. 2009; 169:1224-32.
24. Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. April 29, 2009. Available at http://aidsinfo.nih.gov/ ContentFiles/PerinatalGL.pdf.
25. Mirochnick M, Best B, Stek A, et al. Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr. 2008; 49:485-91.
26. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Atazanavir-ritonavir vs lopinavir-ritonavir in antiretroviral-naive HIV-1 infected patients: 96 week efficacy & safety. Program and abstracts of the 48th ICAAC/46th IDSA; October, 2008; Washington, DC [abstract H-1250d].
27. Noor M, Flint O, Maa J, Parker R. Effects of atazanavir/ritonavir and lopinavir/ ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS. 2006;20:1813-21.
28. Stanley T, Joy T, Hadigan C, et al. Effects of switching from lopinavir/ ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients. AIDS. 2009;23:1349-57.
29. Chan-Tack K, Truffa M, Struble K, Birnkrant D. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System. AIDS. 2007;21:1215-8.
30. Lataillade M, Chiarella J, Yang R, et al. Prevalence and clinical significance of transmitted drug resistant HIV mutations by ultra-deep sequencing in HIV-infected ARV-naïve subjects in the CASTLE study. Antiv Ther. 2009;14(Suppl 1):42.
31. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369:1169-78.
32. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet. 2007;370:49-58.
33. Boffito M, Miralles D, Hill A. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naive and -experienced patients. HIV Clin Trials. 2008;9:418-27.
34. Mills A, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009;23:1679-88.
35. Nelson M, Yeni P, Sension M, et al. Factors affecting virologic response to darunavir/ritonavir and lopinavir/ritonavir in treatment-naïve HIV-1-infected patients in ARTEMIS at 96 weeks. Program and abstracts of the 16th CROI, Montreal, Canada, February, 2009 [abstract 575].
36. Hirsch M, Gunthard H, Schapiro J, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2008;47:266-85.
37. Arathoon E, Baraldi E, Lian Lim P, et al. ARTEMIS: lipid tolerability and safety of darunavir and lopinavir in antiretroviral-naïve patients. Program and abstracts of the XVIIth International AIDS Conference, Mexico City, Mexico, August, 2008 [abstract THPE0151].
38. Baraldi E, Morales-Ramírez J, Schneider S, et al. Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on lipid parameters and anthropometrics in treatment-naïve, HIV-1-infected ARTEMIS patients at Week 96. Program and abstracts of the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, July 2009 [abstract MOPEB034].
39. Arribas JR, Horban A, Gerstoft J, et al. The MONET trial: darunavir/ ritonavir monotherapy shows non-inferior efficacy to standard HAART for patients with HIV RNA <50 copies/mL at baseline. Proceedings of the 5th International AIDS Conference. Cape Town, South Africa. July, 2009 [abstract TUAB106LB].